WAM
CLRB icon

Warberg Asset Management’s Cellectar Biosciences CLRB Stock Holding History

Warberg Asset Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,900
Closed -$35.3K – 175
2026
Q1 		$35.3K Hold
13,900
– – 0.01% 152
2025
Q4 		$41K Buy
+13,900
New +$51.3K ﹤0.01% 145

Other funds holding CLRB

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Warberg Asset Management's CLRB Position: Q2 2026 in Review

Warberg Asset Management sold out of Cellectar Biosciences (CLRB) in Q2 2026, closing a stake of 13,900 shares — an estimated $35.3K sold.

Warberg Asset Management first reported a position in CLRB in Q4 2025 and held it in 2 quarters. The position peaked at $41K in Q4 2025. 29 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Warberg Asset Management reported no remaining Cellectar Biosciences position as of Q2 2026 after selling out during the quarter.
  • Warberg Asset Management sold 13,900 Cellectar Biosciences shares in Q2 2026, an estimated $35.3K.
  • Warberg Asset Management first reported a position in Cellectar Biosciences in Q4 2025 and held it in 2 quarters.
  • Warberg Asset Management's Cellectar Biosciences position peaked at $41K in Q4 2025.
  • 29 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Warberg Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.